As pharma and biotech companies get to grips with shifting sands, what is the impact on the partners they rely on to get drugs to market?

And how can contract manufacturing and development organisations (CDMOs) ensure they’re well-placed to land the deals that will secure their future?

Despite this ambiguity and amid significant consolidation, CDMO growth is set to outpace that of the wider pharma market. In this webinar, we’ll look at what’s driving that expansion, and the areas that offer the most opportunity for CDMOs in 2024 and beyond.